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Available online 28 March 2016Purpose: Develop a minimal mechanistic model based on in vitro–in vivo extrapolation (IVIVE) principles to
predict extent of passive tubular reabsorption. Assess the ability of the model developed to predict extent of
passive tubular reabsorption (Freab) and renal excretion clearance (CLR) from in vitro permeability data and
tubular physiological parameters.
Methods:Model system parameters were informed by physiological data collated following extensive literature
analysis. A database of clinical CLR was collated for 157 drugs. A subset of 45 drugs was selected for model
validation; for those, Caco-2 permeability (Papp) data were measured under pH 6.5–7.4 gradient conditions
and used to predict Freab and subsequently CLR. An empirical calibration approach was proposed to account for
the effect of inter-assay/laboratory variation in Papp on the IVIVE of Freab.
Results: The 5-compartmentalmodel accounted for regional differences in tubular surface area andﬂow rates and
successfully predicted the extent of tubular reabsorption of 45 drugs for which ﬁltration and reabsorption were
contributing to renal excretion. Subsequently, predicted CLR was within 3-fold of the observed values for 87% of
drugs in this dataset, with an overall gmfe of 1.96. Consideration of the empirical calibration method improved
overall prediction of CLR (gmfe = 1.73 for 34 drugs in the internal validation dataset), in particular for basic
drugs and drugs with low extent of tubular reabsorption.
Conclusions: The novel 5-compartment model represents an important addition to the IVIVE toolbox for
physiologically-based prediction of renal tubular reabsorption and CLR. Physiological basis of themodel proposed
allows its application in future mechanistic kidney models in preclinical species and human.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Renal excretion is considered a major route of elimination for many
drugs (e.g., metformin, acyclovir and digoxin) (Morrissey et al., 2013;
Tucker, 1981; Varma et al., 2009). Prediction of human renal excretion
clearance (CLR) prior to commencing ﬁrst-in-man clinical studies
currently relies on in silicomethods based on physico-chemical proper-
ties (Dave and Morris, 2015a; Ito et al., 2013; Paine et al., 2010; Varma
et al., 2009) and/or allometric scaling (Huh et al., 2011; Paine et al.,
2011). Despite wide use of these methods, they do not provide
mechanistic insight into the underlying processes contributing to
renal excretion and have limited ability to account for any changes in
the renal physiology. Mechanistic understanding of various pharmaco-
kinetic (PK) processes has become a necessary part of model-
informeddecisionmaking for special populations (e.g., obese or patients
with renal impairment), as well as devising dosage regimens for use in
such populations (Jadhav et al., 2015). The mechanistic approach
becomes even more important when certain sub-groups (‘complex’
patients) exhibit various co-morbidities which make clinical studiesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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standing various elements of renal excretion may offer advantages
through prediction of potential differences in various patients under
the framework of physiologically-based pharmacokinetic (PBPK)
modelling (Zhao et al., 2011). In addition, many currently developed
drugs undergo extensive active tubular secretion (Morrissey et al.,
2013) for which prediction of CLR by mechanistic PBPK models
(Felmlee et al., 2013; Neuhoff et al., 2013; Posada et al., 2015) is consid-
eredmore promising in comparisonwith in silico and allometric scaling.
While efforts have beenmade at predicting renalmetabolic clearance
from in vitro data (Gill et al., 2012, 2013), successful prediction of CLR
using in vitro–in vivo extrapolation (IVIVE) remains a challenge. In
order to quantitatively and mechanistically predict CLR using IVIVE,
each of the contributing processes (glomerularﬁltration, active secretion
and tubular reabsorption, Eq. (1)) must be considered independently.
CLR ¼ CLR;filt þ CLR; sec
  1 Freabð Þ ð1Þ
Filtration clearance (CLR,ﬁlt) is readily predicted from glomerular ﬁl-
tration rate (GFR) and fraction unbound in plasma (fu,p). In cases where
both secretion and reabsorption contribute to elimination, conﬁdence in
prediction of the fraction reabsorbed (Freab) is equally important as the
accurate prediction of renal secretion clearance (CLR,sec). Whereas
reabsorption is predominantly a passive process, secretion is actively
mediated by a range of drug transporters expressed in the kidney
such as OAT1, OAT3, OCT2 and MATE2-K (Morrissey et al., 2013).
A number of mathematical models concerning physiological functions
of the kidney (e.g., urine concentratingmechanism, solute transport regu-
lation) exist (Layton, 2011; Weinstein, 2015), but may not be readily
adaptable for use in renal PBPKmodels. Further, thesemodelswere devel-
oped based on physiological and experimental data in rat kidney (e.g.,
from micropuncture studies) for which analogous data in human are
lacking. Recently, a static model for the prediction of CLR using in vitro
permeability data fromLLC-PK1 cellmonolayerswas proposed and its per-
formance was assessed against a relatively small and restricted dataset
(Kunze et al., 2014). Themodel consideredboth active secretion and tubu-
lar reabsorption, and used the proximal tubule surface area as the IVIVE
scaling factor for the apparent permeability (Papp) data. However, the
remaining tubular regions (e.g., collecting duct), which may contribute
to passive tubular reabsorption, were not considered (Kunze et al., 2014).
A dynamic kidney model that facilitates IVIVE of renal transporter
kinetics and passive permeability has recently been reported (Neuhoff
et al., 2013). Although very promising, paucity of data on relevant
physiological scaling factors and some of the system data (e.g., transport-
er abundance) limit model application and validation. In addition,
adequate consideration of the heterogeneity of the renal tubule, impor-
tant for prediction of passive permeability clearance in each tubular
segment, is lacking. Current reports on the use of physiologically-based
kidney models for ‘bottom-up’ prediction of renal drug disposition
often rely on clinical plasma and/or urine drug concentration data for
derivation/optimisation of transporter kinetic parameters and their
scaling factors (Dave and Morris, 2015b; Felmlee et al., 2013; Hsu et al.,
2014; Watanabe et al., 2011), analogous to the trends seen with predic-
tion of hepatic clearance (Galetin, 2014; Zamek-Gliszczynski et al., 2013).
For example, IVIVE of human CLR,sec from in vitro uptake data obtained in
precision cut kidney slices required an empirical scaling factor of 10 in
order to obtain agreement between predicted and observed values
(Watanabe et al., 2011). In an analogous manner OAT3 maximal uptake
rate (Vmax) was optimised using plasma concentration–time proﬁles to
reﬁne prediction of pemetrexed CLR using a PBPK kidney model, and
account for differences in transporter expression and activity between
the in vitro transfected cell system and in vivo (Posada et al., 2015).
The aim of this study was to develop a mechanistic model to predict
extent of passive tubular reabsorption from in vitro permeability data
and tubular physiological parameters. The second aim was to assess
the ability of the model developed to predict CLR for a range of drugsfor which ﬁltration or reabsorption appeared to be the dominant
mechanisms contributing to CLR. The physiological aspects of the
model were informed from the data collated following an extensive
literature analysis. A database of in vivo CLR and corresponding Freab
was collated for 157 drugs. For a subset of 45 selected drugs, in vitro
permeability data were generated in Caco-2 cell monolayer under
pH 6.5–7.4 gradient conditions. Subsequently, the tubular reabsorption
model developed was applied to predict regional and overall passive
tubular reabsorption for the selected drug subset (n=45). An empirical
calibration approach was proposed to account for the effect of inter-
assay/laboratory variation in Papp on the IVIVE of Freab using a set of
reference drugs as calibrators (n = 11). The novel mechanistic 5-
compartment model developed enables prediction of the contribution
of passive tubular reabsorption to CLR in a physiologically-based
manner and is seen as an integral part of complex kidney models.
2. Materials and methods
2.1. Clinical data collation
CLR data were collated from literature sources and, wherever
possible, data were acquired from primary studies. Further data were
gathered from review papers where sufﬁcient details on the trial design
had been reported. In addition, data from unpublished clinical studies
available at https://www.clinicaltrials.gov were also included in the
analysis. Where CLR values were not reported in the study, Eqs. (2) and
(3) were used to calculate CLR from published urinary excretion and
plasma concentration data. Reports of a drug not being detected
unchanged in urine, or having “negligible” CLR, were not considered for
collation. Data available in graphical formatwere digitised using GetData
Graph Digitizer v2.25 (http://getdata-graph-digitizer.com/).
CLR ¼ Amount excreted in urine 0tAUC0t ð2Þ
CLR ¼ Urinary excretion rateCp;midpoint
ð3Þ
where AUC0-t represents the area under the plasma concentration–time
proﬁle, and Cp,midpoint represents the plasma concentration at the
midpoint of the urinary collection interval from which the urinary
excretion rate was measured.
Only CLR data acquired following administration of a drug to healthy
adult subjects were included in the database. Data fromdiseased, obese,
elderly or alcoholic subjects were excluded, but exclusion criteria based
on sex or ethnicity were not applied. Data acquired after co-
administration of multiple drugs (e.g., from drug–drug interaction
studies)were generally excluded. An exceptionwasmade for trimetho-
prim and sulfamethoxazole because these drugs are generally co-
administered and there is a paucity of data following single drug
administration. These studies were considered acceptable as there
have been no reports in the literature of interactions at the level of
renal excretion between sulfamethoxazole–trimethoprim. Aminoglyco-
sides (amikacin, gentamicin, isepamicin, netilmicin, sisomicin and
tobramycin) were excluded. These drugs are reported to accumulate
in proximal tubule cells, possibly due to endocytotic luminal uptake
mediated by the megalin receptor, causing nephrotoxicity (Moestrup
et al., 1995; Nagai and Takano, 2004; Schmitz et al., 2002). Drugs with
enantiomer speciﬁc renal excretion were excluded, an example being
cetirizine (Strolin et al., 2008).
In contrast to previous databases (Varma et al., 2009), CLR data in
this database are reported as absolute values, i.e.without normalisa-
tion for body weight or body surface area. Normalisation was not
considered as the majority of literature studies (N75%) reported ab-
solute CLR values and substantial portion of studies did not report ei-
ther body weight or body surface area of subjects. In addition, recent
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and creatinine clearance for the drug dosing recommendation, in
contrast to body surface area normalised values (Chew-Harris
et al., 2015; Dooley and Poole, 2000; Jones, 2011; Pai, 2010). In
cases where CLR data were reported following normalisation to
body weight (e.g., mL/min/kg or mL/min/70 kg), CLR data were
corrected according to the mean weight or midpoint of the range re-
ported in the study. The CLR data were corrected using an assumed
body weight of 70 kg for those studies in which body weights had
not been reported, which could have introduced some bias. An anal-
ogous approach was applied for CLR data reported following
normalisation to body surface area, using a standard value of
1.73 m2 for studies where subject body surface area data was not
reported.
When clearance values for the same drug were available from
multiple sources, anomalies in studies/trials reported for individual
drugs were initially identiﬁed using the I2 statistic for data heterogene-
ity (Eqs. (4) and (5)) (Higgins and Thompson, 2002; Higgins et al.,
2003). High heterogeneity was observed for 20 drugs (I2 greater than
0.5), of which 8 had very high heterogeneity (I2 greater than 0.75).
The presence and subsequent exclusion of anomalous studies/trials
was identiﬁed for drugs with I2 greater than 0.5 through visual analyses
of study/trial mean and standard deviation data.
I2 ¼ 100%  Q  df
Q
ð4Þ
where Q is Cochran's heterogeneity statistic, and df is the degrees of
freedom
Q ¼∑
yi 
∑
yi
σ2i
∑ 1
σ2i
 !2
σ2i
ð5Þ
where yi is the mean CLR reported by study i, and σ2i is the variance in
CLR reported by study i.
In addition to CLR, any measured or estimated creatinine clearances
and GFR that had been reported in the same clinical studies were
collated where available. These data were corrected for any
normalisations that had been applied, as performed for CLR. Data report-
ed on fu,p were also collated from the same study. Further fu,p data were
obtained using other literature sources. Where nonlinear plasma
protein binding was reported for a drug, the fu,p at concentrations
consistent with plasma concentrations reported for CLR clinical studies
were used for the analysis.
The fu,p data were collated from a variety of in vivo and in vitro
sources using a number of different experimental techniques (ultraﬁl-
tration or membrane dialysis). Therefore, the average fu,p value for
each drug was obtained without applying a weighting, whilst ensuring
good agreement was achieved between the data used to obtain the
average.
Overall weighted mean CLR and standard deviation were calculated
using Eqs. (6) and (7), respectively.
WX ¼∑
J
j¼1 nj∙xj
∑ Jj¼1 nj
ð6Þ
where WX is the weighted mean, nj is the number of subjects in the jth
study, andxj is themean of the jth study. Here a “study” is deﬁned as the
data associated with a group of subjects being administered a speciﬁc
dose regime, on a particular occasion, with “n” number of subjects.
σ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑ Jj¼1 σ j
2 þ xj2
 
nj
h ih i
 ∑ Jj¼1 nj
 
∙WX
2
h i
∑ Jj¼1 nj
vuuut ð7Þwhere σ is the overall weighted standard deviation and σj is the
standard deviation of the jth study.
2.2. Calculation of observed clearance ratio and Freab
The clearance ratio was calculated from clinical data using
Eqs. (8) and (9), in agreement with reported studies (Giacomini et al.,
2010; Ito et al., 2013). Drugs with a clearance ratio greater than 1.5
were considered to undergo net secretion, andwere therefore excluded
from subsequent analyses and assessment of the model developed for
prediction of tubular reabsorption. For the remaining drugs the fraction
reabsorbed (Freab) was calculated using Eq. (10).
CLR;filt ¼ GFR fu;p ð8Þ
Clearance Ratio ¼ CLR
CLR;filt
ð9Þ
Freab ¼ 1
CLR
CLR;filt
ð10Þ
N.B. In certain instances, calculated Freab was negative based on
Eq. (10). For these drugs (6/45 drugs), data in ﬁgures were presented
as Freab = 0 (actual negative values were used for numerical analyses).
The most extreme example was atenolol, with the observed weighted
overall CLR of 145 ± 48 mL/min (fu,p of 0.97) which exceeded GFR as-
sumed in the current study.
GFR values for healthy subjects may vary as a result of biological as
well as inter-individual variation and also the method of measurement.
As the more robust methods for measuring GFR, such as inulin or
iohexol renal clearance, are impractical and time consuming (Sterner
et al., 2008), GFR measurements during clinical studies are typically
based on the renal clearance of endogenous creatinine. This method is
associated with a degree of inaccuracy, due to the proposed contribu-
tion of active secretion by the OCT2, MATE1 and MATE2-K transporters
to creatinine clearance (Soveri et al., 2014; Tanihara et al., 2007;
Urakami et al., 2004). More frequently GFR is not measured but
estimated using creatinine plasma concentrations using either the
‘Cockcroft–Gault’ or ‘Modiﬁcation of Diet in Renal Disease’ equations
(Nyman et al., 2011). Individual GFR values for subjects in clinical trials
databases were generally not available. Therefore, for the purposes of
this study, a GFR value of 120mL/minwas assumed for all drugs, consis-
tent with precedent set in the literature and value used in the recently
developed physiologically-based kidney model (Delanaye et al., 2012;
Neuhoff et al., 2013).
2.3. In vitro permeability data, physico-chemical properties and drug
afﬁnity for renal transporter proteins
In the absence of a robust and validated in vitromodel for assessing
passive permeability in the renal nephron tubule, it was hypothesised
that permeability data obtained in Caco-2 cell monolayers may offer a
potential substitute. Apparent permeability (Papp) of drugs was mea-
sured in the apical to basolateral direction in Caco-2 cell monolayers
using an AstraZeneca in-house assay (Hilgendorf, C. and Fredlund, L.,
Intrinsic permeability in-vitro — a transporter independent measure of
Caco-2 permeability in drug design and development; poster presented
at World Conference on Drug Absorption, Transport and Delivery
(WCDATD): responding to challenging situations; Uppsala, Sweden
June 24–26, 2013). The assay was performed using the apical to
basolateral pH gradient format of pH 6.5 to pH 7.4. Permeability assays
were performed in the presence of an efﬂux transporter inhibitor
cocktail (50 μMquinidine, 20 μMsulfasalazine, 100 μMbenzbromarone)
over a 2 h incubation period. The pH gradient was applied in order to
mimic typical conditions observed in the renal tubule, where the urine
pH can vary between 4.5 and 8, but is typically more acidic relative to
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hibitor cocktail was used to minimise the effect of efﬂux transporters
expressed in Caco-2 cells (e.g. P-glycoprotein, BCRP and MRP2) on the
estimate of apical to basolateral Papp of substrates for such transporters.
Papp data were obtained for a subset of drugs that exhibited a variety of
physico-chemical properties, range of CLR, Freab and expected Papp
values (based on historical AstraZeneca in-house data and literature
analysis of permeability data generated under isotonic pH 7.4
conditions).
The octanol-buffer (pH 7.4) distribution coefﬁcient (LogD7.4) and
pKa data were generated using slight modiﬁcation of the shake-ﬂask
(Wenlock et al., 2011) and potentiometric AstraZeneca in-house as-
says respectively. Where measured LogD7.4 or pKa data could not be
obtained, values reported in the BioByte Masterﬁle database
(BioByte Corporation, Claremont, CA, USA, http://www.biobyte.
com/index.html) or calculated using ACD/LogD program v.14.02
(Advanced Chemistry Development, Inc., Toronto, On, Canada,
www.acdlabs.com, 2014) were used. The pKa values associated
with ionisable centres identiﬁed within a given drug were used to
calculate the fraction of drug ionised at pH 6.5. Drugs were then
classiﬁed into groups as follows: drugs with N50% unionised at
pH 6.5 were classiﬁed as “Neutral”; drugs with N50% ionised as
mono−/di−/tri-protic acids or bases were classiﬁed as “Acid” or
“Base”, respectively; “Zwitterions” were classiﬁed as drugs with
N50% ionised, with the major ionised species having no net charge;
all other drugs were classiﬁed as amphoteric. The LogD6.5 of acids
and bases were estimated from LogD7.4 and pKa data assuming that
only the neutral species partitions into the octanol phase (Kah and
Brown, 2008). LogD6.5 for neutral, amphoteric and zwitterion drugs
were assumed to be equal to LogD7.4. Although melagatran,
oxytetracycline and tetracycline have an isoelectric point N7.4 or
b6.5, the difference between LogD7.4and LogD6.5 predicted by ACD
was less than 0.5, conﬁrming the validity of the assumption above.
The potential impact of renal transporter mediated secretion of
drugs on the assessment of the prediction of CLR using the minimal
model of reabsorption was investigated. A thorough literature search
was performed in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) to
identify drugs reported to be substrates of OAT1, OAT3, OAT4,
OATP4C1, OCT2, OCTN1, OCTN2, MATE1, MATE2K, P-gp, MRP2, MRP4
or BCRP (Morrissey et al., 2013). To expand this dataset, the UCSF-FDA
Transportal and TP-search databases were also searched (Morrissey
et al., 2012; Ozawa et al., 2004). Only reports of drugs interacting as sub-
strates of human drug transporters were included. In addition, clinical
data indicating occurrence of renal transporter mediated drug–drug in-
teractions (i.e., decrease in CLR following co-administration of another
drug) were used as indirect evidence of drugs being substrates of
renal drug transporters.
2.4. Overall structure of the minimal model of tubular reabsorption
In the proposed model, the nephron is represented as ﬁve com-
partments, namely the glomerulus and four tubular regions, as
depicted in Fig. 1. The tubular compartments in the model, listed in
anatomical order starting from the glomerulus are: the proximal tu-
bule (PT), the loop of Henle (LoH), the distal tubule (DT) and the
collecting duct (CD). In the absence of active processes, tubular reab-
sorption proceeds until the urinary concentration is in equilibrium
with the unbound drug plasma concentration. Thus a Freab value of
1, and CLR of 0, is not strictly possible in this case. The minimal
model of reabsorption was developed by introducing an intermedi-
ary parameter, Freab′, the value of which could range from 0 to 1,
representing the fraction of the equilibrium reached between urine
and plasma. The relationship between Freab′ and Freab is shown in
Eq. (11). The predicted overall Freab′was calculated from the predict-
ed Freab′ in each (i) tubular region (Freab,i′), as shown in Eq. (12).
Regional Freab,i′ (Eq. (13)) were predicted from the intrinsicpermeability clearance of the drug of interest for each tubule region
(CLR,int,reab,i) and the tubular ﬂow rate (TFR) of the ﬁltrate/urine in
the corresponding region (TFRi), approach adapted from previous
studies (Kunze et al., 2014).
Freab
0 ¼ Freab 
CLR;filt
CLR;filt  UF fu;p
  ð11Þ
where UF is the urine ﬂow, which was assumed to be 1 mL/min
Freab 0 ¼ 1∏ 1 Freab;i 0
  ð12Þ
Freab;i
0 ¼ CLR;int;reab;i
TFRi þ CLR;int;reab;i
: ð13Þ
CLR,int,reab,i for each drug and tubular region combination was
calculated using an IVIVE approach, as per Eq. (14) (Kunze et al., 2014).
CLR;int;reab;i ¼ Papp  TSAi ð14Þ
where TSAi is the tubule surface area for each individual tubular region.
Based on the scope of the model, renal drug metabolism was not
considered. In addition, there was no evidence of renal metabolism for
the majority of drugs used to assess the predictive performance of the
model of reabsorption.
2.5. Minimal model of tubular reabsorption: Physiological system
parameters
Final values of physiological input parameters for the four tubular
compartments are shown in Table 1, with the full detail on the individ-
ual parameters (e.g., tubular region diameters and length) presented in
the Supplementary Methods. In general, TFRi values were the midpoint
ﬂow rates for each tubular compartment (Table S1.1 and S1.2). TSAi
values were initially calculated following the assumption of the surface
area of a cylinder, using length and diameter of tubular region
(Tables S1.3 and S1.4), and the number of nephrons of 900,000 neph-
rons/kidney. Special consideration was made for the CD compartment,
due to the merging of nephrons to form the cortical CD, and merging
of CDs in the innermedulla. To account for this, the number of nephrons
was reduced to 90,000 nephrons/kidney for the cortical and outer
medulla CD, with surface area calculated following assumption of a
cylinder. The surface area of the inner medulla CD was calculated
using an exponential function shown in Eq. (15) (details provided in
Supplementary Methods, Section 2 and Fig. S1.1) which accounts for
the concomitant decrease in number and increase in diameter of CD,
as they traverse towards the renal pelvis.
Cx ¼ d0 NCD0  πð Þe
x F
nð Þ ln 2
d0
dn
1
F
0
@
1
A
0
@
1
A
ð15Þ
where d0 and dn are the diameter of inner medulla collecting ducts at
the papilla apex and at the outer medulla-inner medulla boundary,
NCD0 is the number of inner medulla CD at the papilla apex, and F is
the number of fusion events. Cx represents the total circumference of
inner medulla CD throughout this region at ‘x’ mm from the papilla
apex. The inner medulla CD surface area is the area under the curve of
this function between 0 and n, where n is the length of the IMCD
(length = inner medulla width = 11 mm).
Microvilli are present extensively in epithelial cells of the proximal
tubulewhere they form a brush border; in contrast,microvilli are sparse
in tubular cells of other regions (Welling et al., 1981; Welling and
Welling, 1988). Additionally, there is evidence of the expression of mi-
crovilli in the Caco-2 cells. Therefore, a microvilli correction factor was
applied to TSAi values in the DT, LoH and CD compartments to account
for the differential presence of microvilli along the renal tubule relative
Fig. 1. Schematic diagram of the minimal physiologically-based model for tubular reabsorption of drugs in the kidney. The nephron is represented by a glomerulus compartment in
addition to four compartments representing different regions of the nephron tubule (proximal tubule (PT), loop of Henle (LoH), distal tubule (DT) and collecting duct (CD) in
descending anatomical order). Physiological parameters, tubular ﬂow rate (TFRi) and tubular surface area (TSAi), for each individual tubular region are indicated. Tubular ﬁltrate ﬂow
(Q) is represented by grey arrows connecting tubular compartments and used to calculate TFRi (average midpoint ﬂow rates). The intrinsic reabsorption clearance of each individual
region (CLR,int,reab,i) is calculated using the corresponding TSAi. Total renal excretion clearance (CLR) is obtained from the ﬁltration clearance (CLR,ﬁlt) and the overall fraction
reabsorbed (Freab), by rearrangement of Eq. (9).
Table 1
Physiological parameter values used for tubular compartments in the minimal physiolog-
ically-based reabsorption model.
TSAi (m2) TFRi (mL/min)a
PT 6.1 81.6 (120–43.2)
LoH 0.16b 33.6 (43.2–24.0)
DT 0.21b 17.8 (24.0–11.6)
CD 0.045b,c 6.3 (11.6–1.0)
a Values represent midpoint ﬂow rates, ranges in parentheses represent ﬂows at be-
ginning and end of tubule regions.
b TSALoH, TSADT and TSACD calculated accounting for microvilli.
c TSACD includes an exponential function for calculating surface area of inner medulla
CD. Details are listed in the Supplementary Methods.
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crease in the estimated surface area compared to that calculated using
the assumption of open cylinder for the LoH, DT and CD compartments.
The method used here is analogous to a recently published approach to
estimate speciﬁc regional effective permeability for intestinal PBPK
models used to predict drug absorption (Olivares-Morales et al., 2015).2.6. Empirical relationship between Papp and observed Freab′
The empirical relationship between Papp and Freab′ was best
described by the Hill model (Eq. (16)), consistent with the relation-
ship already deﬁned between Papp across Caco-2 cell monolayers and
64 D. Scotcher et al. / European Journal of Pharmaceutical Sciences 94 (2016) 59–71fraction absorbed following oral administration (Artursson et al.,
2001).
Freab 0 ¼
Pappa
ba þ Pappa
ð16Þ
where a represents the slope factor and b is the value of Papp at which
Freab′ equals 0.5. The Hill model was ﬁtted to the data using nonlinear
regression to estimate best-ﬁt values and 95% conﬁdence interval
(CI) of parameters.
2.7. Calibration of Caco-2 permeability data
Permeability data fromCaco-2 cell monolayer assays generally show
inter-laboratory variation (Artursson et al., 2001). To account for this
and to allow the Caco-2 data in the present study to be transferable to
other assay formats/laboratories, a Papp–Freab′ calibration method was
explored by splitting the available Papp and Freab′ data into ‘reference’
and internal ‘validation’ subsets. It is important to clarify that this
calibration is not intended to predict Freab′ using a data driven empirical
model, as done in quantitative structure–pharmacokinetic relationship
models, which require formal internal and external validation (Dave
andMorris, 2015a). The calibration approach is proposed as a pragmatic
method to account for inter-assay/inter-laboratory differences; herein it
is applied to the current dataset only, and not external data as intended
for future studies.
The reference drugs (n= 11) were selected to cover a range of Papp
and Freab′ values and were representative of the overall relationship be-
tween Papp and Freab′. The relationship between Papp and the predicted
Freab′ based on the minimal reabsorption model was best described by
theHillmodel, analogous to the relationship between Papp and observed
Freab′ discussed above. Empirical calibration was performed using the
reference dataset of 11 drugs to account for any discrepancy between
predicted and observed Freab′. This approach allowed subsequent calcu-
lation of calibrated Papp values for the drugs in the internal validation
dataset (n = 34), using Eq. (17) (see Supplementary Methods for
derivation).
Papp;calibrated ¼
b1  Papp
a2
a1
 
b2
a2
a1
  ð17Þ
where a1 and b1 are the slope factor and Papp value at which Freab′ is
equal to 0.5 for the Papp vs Freab′Hill equation ﬁtted against data predict-
ed by theminimalmodel for the reference dataset; a2 and b2 are theHill
equation parameters obtained from ﬁtting Papp values for the reference
drugs (Papp,ref) and corresponding observed Freab′.
2.8. Data analysis
Nonlinear regression was carried out using MATLAB R2012a (The
MathWorks Inc., Natick, MA, USA, www.mathworks.com). All other
data analyses were performed using MS Excel. The model perfor-
mance was assessed based on the R2 of the predicted vs. observed
linear regression, and by considering the number and percent of
drugs predicted within 3-fold of the observed CLR. The performance
of models with different physiological complexity was assessed for
drugs with low (Freab b 0.25), medium (Freab = 0.25–0.75) and high
passive tubular reabsorption (Freab N 0.75). These cut-off values
were arbitrarily selected to assess potential differences in trends be-
tween these groups of drugs.
Bias and precision in predicting CLR and Freab were calculated as
geometric fold error (gmfe) in Eq. (18) and root mean squared error
(rmse) in Eq. (19) (Gertz et al., 2010). The gmfe indicates an absolute
deviation from the observed data, as this metric does not allow over-and under-predictions to cancel each other out.
gmfe ¼ 101n∑ log10 PredictedObservedð Þj j ð18Þ
RMSE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
∑ log Observedð Þ  log Predictedð Þð Þ2
r
: ð19Þ
3. Results
3.1. Collation of a comprehensive renal clearance database
CLR, fu,p and transporter interaction data were collated for 157
drugs; details are listed in Supplementary Material, Tables S2.1 and
S3.1. On average 4–5 clinical studies and 40 CLR measurements
were obtained per individual drug, although this varied depending
on availability of data. No attempt was made to separate intra- and
inter-subject variability. Following analysis using the I2 statistic,
three studies/trials were classiﬁed as anomalous results and
excluded; details are presented in the Supplementary Results,
Table S4.1. Overall weightedmean CLR ranged from 0.022 (isoxicam)
to 526 mL/min (metformin), while fu,p ranged from 0.01
(olmesartan) to 1 (metformin). Measurements and estimates of
GFR (n = 1686) were reported from 200 clinical studies (28% of
studies collated). Only two of the studies collated used inulin to
measure GFR; the remainder used either creatinine clearance,
estimated GFR from plasma creatinine concentrations, or did not
specify the method. Overall weighted mean GFR was 112.9 ±
25.2 mL/min, with study mean values ranging from 69.2 to
168.0 mL/min.
Of the 157 drugs, 72 were classiﬁed as net secreted (clearance
ratio N 1.5). As such, they were regarded unsuitable for assessing a
model of tubular reabsorption and therefore excluded from further
analysis. Glomerular ﬁltration or reabsorption was the dominant
mechanism for the remaining 85 drugs (clearance ratio b 1.5). Of
these, a representative subset of 45 drugs was selected for the
assessment of the predictive performance of the mechanistic tubular
reabsorption model. These drugs covered a range of CLR values, from
0.02 (isoxicam) to 145 mL/min (atenolol); the extent of tubular
reabsorption ranged from none (six drugs including atenolol and
verapamil) to reaching complete equilibrium (Freab′ = 1, isoxicam).
Drugs were also selected to ensure a range of physico-chemical
properties were represented, although neutral and basic drugs
represented the majority, with 15 and 16 drugs, out of the set of 45,
falling into these categories, respectively (Table 2). Approximately one
third of the drugs have been reported to be substrates of human drug
transporters known to be expressed in the kidney. Corresponding Papp
values obtained in the Caco-2 cells under the 6.5–7.4 pH gradient
conditions covered approximately 3 orders of magnitude, as shown in
Table 2.
Lipophilic drugs, and those unionised at physiological pH,were asso-
ciated with low CLR, (Supplementary Results, Figs. S4.1 and S4.2), in
agreement with previous studies (Paine et al., 2010; Varma et al.,
2009). No clear trends could be established between LogD7.4 or
LogD6.5 and observed Freab of 45 drugs investigated (data not shown).
High LogD7.4 did not appear to be predictive of high tubular reabsorp-
tion (Freab N 0.75), as a wide range of LogD7.4 values were associated
with drugs in moderate to low Freab category (Supplementary Results
Fig. S4.1). The majority of neutral drugs (62%) had high tubular reab-
sorption (Freab N 0.75), whereas the majority of ionised drugs had low
Freab (b0.25). The percent of acidic, basic, zwitterion and amphoteric
drugs with Freab b 0.25 was 43%, 56%, 61% and 100%, respectively (data
presented in detail in the Supplementary Results, Fig. S4.2).
Table 2
In vivo, physico-chemical properties and in vitro data for 45 drugs used to assess the minimal model of tubular reabsorption.
References for CLR and indications of transporter afﬁnity are provided in Supplementary Results Tables S2.1 and S3.1.
Drug CLR
(mL/min)
Freaba Papp
(×10−6 cm/s)
fu,p pKa (acid) pKa (base) Ionisation at
pH 6.5b
LogD7.4 LogD6.5c Indication of transporter
afﬁnity
Antipyrine 1.22 0.99 125 0.89 – – Neutral 0.11 0.11 N/A
Aprindine 1.28 0.78 31.8 0.05 – 9.95, 5.85d Base 2.50 1.53 N/A
Atenolol 145 −0.25 0.256 0.97 – 9.39 Base −2.65 c −3.55 OCT2
Betamethasone 9.50 0.78 26.5 0.36 – – Neutral 1.99 1.99 P-gp
Betaxolol 49.6 0.08 20.0 0.45 – 9.53 Base 0.63 −0.27 N/A
Caffeine 1.06 0.99 81.1 0.67 – – Neutral 0.11 c 0.11 N/A
Chlorpheniramine 26.2 0.26 28.5 0.30 – 9.35, 5.15 Base 1.22 0.31 N/A
Chlorpropamide 0.56 0.91 88.1 0.05 4.69 – Acid −0.33 0.56 N/A
Citalopram 65.2 −0.09 20.9 0.50 – 9.57d Base 1.55 0.65 N/A
Dapsone 5.50 0.83 49.7 0.27 – – Neutral 0.85 0.85 N/A
Diﬂoxacin 4.54 0.94 74.6 0.62 5.81 7.39 Zwitterion 0.70 0.70 N/A
Doxepin 9.75 0.64 36.5 0.22 – 8.00d Base 2.23 1.41 N/A
Fluconazole 15.7 0.85 36.3 0.86 – – Neutral 0.46 0.46 P-gp
Gabapentin 95.1 0.18 0.67 0.97 4.72d 10.27d Zwitterion −1.10 −1.79 OCTN1
Grepaﬂoxacin 47.6 0.35 110 0.61 6.44d 8.74d Zwitterion 0.50 0.50 P-gp
Imipramine 6.80 0.55 33.4 0.13 – 9.17 Base 2.49 1.60 N/A
Irbesartan 2.37 0.62 44.0 0.05 3.91 – Acid 1.29 2.19 N/A
Isoxicam 0.02 1.00 142 0.04 3.84 – Acid −0.20 0.70 N/A
Levetiracetam 39.4 0.64 15.7 0.90 – – Neutral −0.63 c −0.63 N/A
Linezolid 39.5 0.58 36.1 0.78 – – Neutral 0.67 0.67 N/A
Melagatran 114 −0.02 0.145 0.93 2.12 11.62, 8.16d Amphoteric −1.42 −1.42 P-gp
Metoprolol 110 −0.05 17.0 0.87 – 9.40 Base −0.29 −1.19 OCT2
Metronidazole 9.64 0.92 64.7 0.98 – – Neutral −0.11 −0.11 N/A
Mexiletine 71.6 −0.25 43.8 0.48 – 9.13 Base 0.62 −0.27 N/A
Moclobemide 3.42 0.94 64.4 0.50 – 6.53d Base 1.60 1.34 N/A
Moxiﬂoxacin 42.7 0.37 26.7 0.57 6.31 9.51 Zwitterion −0.24 −0.24 P-gp, MRP2
Oxprenolol 9.35 0.44 30.0 0.14 – 9.60 Base 0.23 −0.67 N/A
Oxytetracycline 90.8 0.02 0.850 0.77 3.27, 7.32, 9.11d 10.80d Zwitterion −4.7c −4.70 P-gp
Peﬂoxacin 12.9 0.86 63.7 0.75 6.28 7.55 Zwitterion 0.30 0.35 P-gp
Prednisolone 34.3 0.10 19.7 0.32 – – Neutral 1.62c 1.62 P-gp
Prednisone 37.9 0.30 37.3 0.45 – – Neutral 1.25 1.25 Weak P-gp interaction
Probenecid 0.50 0.96 84.5 0.09 3.36 – Acid −0.14 0.76 N/A
Propafenone 7.37 0.26 26.4 0.08 – 9.62d Base 1.72 0.82 N/A
Propylthiouracil 3.20 0.83 80.8 0.16 8.01 – Neutral 0.70 0.78 N/A
Ribavirin 109.9 0.08 1.55 1.00 – – Neutral −2.14c −2.14 N/A
Ropivacaine 2.73 0.55 32.3 0.05 – 8.10 Base 2.10 1.27 N/A
Sparﬂoxacin 21.7 0.73 49.8 0.67 6.31 8.94 Zwitterion −0.15 −0.91 P-gp
Sulfamethoxazole 4.52 0.89 41.7 0.35 5.81 – Acid −0.63 0.20 N/A
Tetracycline 86.4 0.05 1.10 0.76 5.06, 7.63, 8.77d 10.52d Zwitterion −0.90 −0.90 Weak OAT3 interaction
Theophylline 5.50 0.91 65.1 0.52 8.51 – Neutral −0.09 −0.06 N/A
Tocainide 67.5 0.18 19.0 0.69 – 7.75d Base 0.03 −0.73 N/A
Topiramate 15.1 0.86 46.2 0.87 9.22d – Neutral 0.60 0.61 MATE2K
Venlafaxine 80.0 0.09 27.6 0.73 – 9.64 Base 0.95 0.05 N/A
Verapamil 25.6 −0.35 20.9 0.16 – 8.74 Base 2.61 1.73 P-gp, OCTN1, OCTN2
Voriconazole 1.57 0.97 96.5 0.42 – – Neutral 1.70 1.70 N/A
N/A No information available whether a drug was a substrate for renal drug transporters.
a Apparent negative Freab are result of inclusion criteria (CR b 1.5) and were changed to 0 for graphical presentation.
b Drugs were classiﬁed using the predominant species (N50%) at pH 6.5, using either measured or calculated pKa data.
c LogD6.5 calculated from pKa and LogD7.4, as described in the methods.
d LogD7.4 and pKa values predicted using ACD (v.14.02) or obtained from BioBytes Masterﬁle (otherwise measured experimentally as described in the methods).
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Predictive performance of the tubular reabsorption model was
assessed using a subset of 45 drugs. Initial analysis was performed by
assessing CLR prediction assuming that the glomerular ﬁltration was
the only contributing mechanism (Eq. (8)). This approach resulted in
general over-prediction of CLR, as shown in Fig. 2 and Table 3; the
predicted CLR for each individual drug are listed in the Supplementary
Results, Table S4.2. The extent of over-prediction (N3-fold)was particu-
larly apparent for neutral (10 out of 15 drugs) and acidic drugs (4 out of
5 drugs). Antipyrine (neutral), caffeine (neutral), and isoxicam (acid)
were the most pronounced outliers with the extent of over-prediction
of CLR ranging from 75- to 202-fold for these drugs. Conversely, the
majority of basic drugs were predicted well, especially betaxolol,
citalopram, metoprolol and venlafaxine. For these four basic drugs, the
assumption of glomerular ﬁltration in isolation resulted in predicted
CLR within 10% of the observed values.3.3. Prediction of Freab using the minimal physiologically-based tubular
reabsorption model
The IVIVE approach was used to predict the Freab and CLR from Caco-
2 Papp data using the minimal mechanistic tubular reabsorption model,
as outlined in the Materials and methods (Eqs. (11)–(14)). The
observed Freab was calculated from reported CLR and fu,p data, assuming
the GFR value of 120 mL/min (Fig. 3). In some instances, apparently
negative Freab and Freab′ values were obtained (e.g., atenolol and
verapamil); this is an artefact of the inclusion criteria applied, given
that the renal clearance ratio was used as cut off for net secretion
(N1.5). Overall there was a good agreement between predicted and
observed Freab, albeit with over-prediction of Freab for some drugs with
moderate Papp values (~20–40 × 10−6 cm/s).
The predicted CLR were calculated for 45 drugs using the predicted
Freab, togetherwith GFR and urineﬂow (full results listed in Supplemen-
tary Results, Table S4.2). There was a good agreement between
Fig. 2. Comparison of predicted and observed CLR using CLR,ﬁlt alone to predict CLR. Neutral
( ), basic ( ), acidic ( ), zwitterion ( ) and amphoteric ( ) drugs are indicated. Solid and
dashed lines represent line of unity and 3-fold error, respectively.
Fig. 3. Comparison of observed and predicted Freab using the mechanistic tubular
reabsorption model and Papp data obtained in Caco-2 cells. Panel A: Predicted
relationship between Freab and Papp is shown by the solid black line, whereas observed
data are shown by symbols; Panel B: Predicted/observed Freab are plotted as symbols,
whereas solid and dashed black lines indicate Predicted/observed = 1 and 3-fold error,
respectively. Symbols indicate neutral ( ), basic ( ), acidic ( ), zwitterion ( ) and
amphoteric ( ) drugs. Drugs with negative values for observed Freab are plotted as
Freab = 0 in Panel A, or predicted/observed Freab = 100 in Panel B, as described in the
Materials and methods.
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(Fig. 4 and Table 3). In particular, this trend was evident for neutral
drugs (gmfe = 1.86), where 87% of CLR were predicted within 3-fold
error of the observed value with antipyrine and caffeine being the
only exceptions (over-prediction of 4.1 and 6.8-fold, respectively). In
the case of basic drugs, a general CLR under-prediction trend was
noted, as well as poor precision (RMSE = 31.0), in agreement with
the over-prediction of Freab seen for this class of drugs (Fig. 3). Consider-
ation of both glomerular ﬁltration and reabsorption reduced the
prediction accuracy in the case of betaxolol, citalopram, metoprolol
and venlafaxine. However, the predicted CLR was still within 50–65%
of the observed data. Despite this overall CLR under-prediction trend,
it is important to note that the values for the majority of basic drugsTable 3
Assessment of the physiologically-based tubular reabsorptionmodel for prediction of CLR.
Performance of themechanisticmodel was assessed initially for all drugswith ameasured
Caco-2 Papp value with the exception of those that showed evidence of net secretion
(clearance ratio N 1.5). Subsequently, the tubular reabsorptionmodelwas reassessed after
excluding drugs currently identiﬁed as substrates for drug transporters expressed within
kidney.
R2 # (%) of drugs
within 3-fold of
observed CLR
gmfe RMSE
CLR,ﬁlt only
All drugs (45) 0.38 26 (58%) 3.73 43.0
Neutral (15) 0.15 5 (33%) 6.69 63.4
Acid (5) 0.75 1 (20%) 16.45 18.0
Basic (16) 0.84 14 (88%) 1.80 18.0
Zwitterion (8) 0.41 5 (63%) 2.47 44.9
Amphoteric (1) N/A 1 (100%) 1.02 2.3
Minimal model
All drugs (45) 0.76 39 (87%) 1.96 20.9
Neutral (15) 0.86 13 (87%) 1.86 10.4
Acid (5) 0.84 4 (80%) 2.29 2.1
Basic (16) 0.79 14 (88%) 2.18 31.0
Zwitterion (8) 0.84 7 (88%) 1.73 18.3
Amphoteric (1) N/A 1 (100%) 1.03 3.3
Non-substrates of renal transporters (29) 0.65 25 (86%) 2.07 19.3
Neutral (10) 0.95 8 (80%) 1.88 7.2
Acid (5) 0.84 4 (80%) 2.29 2.1
Basic (13) 0.76 12 (92%) 2.19 28.0
Zwitterion (1) N/A 1 (100%) 1.66 3.0
Amphoteric (0) N/A N/A N/A N/A(14/16) were predicted within 3-fold of the observed. Mexiletine and
verapamil were the most pronounced outliers as the predicted CLR
represented only 16 and 29% of the observed value, respectively.Fig. 4. Comparison between observed and predicted CLR by the mechanistic tubular
reabsorption model. Symbols indicate neutral ( ), basic ( ), acidic ( ), zwitterion ( )
and amphoteric ( ) drugs respectively. Solid and dashed lines represent line of unity
and 3-fold error, respectively. The inset shows the data for lower CLR values for clarity.
Table 4
Assessment of the predictive performance of various CLR prediction methods using gmfe and % predicted within 3-fold of observed CLR.
gmfe (% predicted within 3-fold of observed)
Filtration onlya No correction for microvillib Proximal tubule onlyc Reabsorption modeld Papp–Freab′ calibratione
All drugs (n = 45) 3.73 (58%) 5.35 (27%) 2.17 (76%) 1.96 (87%) 1.65 (91%)
Low Freab (n = 17) 1.17 (100%) 5.02 (35%) 1.59 (94%) 1.97 (88%) 1.34 (94%)
Medium Freab (n = 12) 2.56 (75%) 8.52 (17%) 1.44 (92%) 1.90 (92%) 1.73 (92%)
High Freab (n = 16) 16.86 (0%) 4.03 (25%) 4.11 (44%) 2.01 (81%) 1.98 (88%)
a CLR,ﬁlt calculated using Eq. (7) in main text.
b No correction was made for surface area attributable to the presence/absence of microvilli when calculating CLR,int,reab,i.
c CLR predicted using a model with only one tubular compartment representing proximal tubule (main contributor to reabsorption predicted by the model).
d CLR predicted using tubular reabsorption model, as per Eq. (10)–(12).
e CLR predicted using the tubular reabsorption model after calibration of Papp data using Eq. (14), data are for all drugs including reference subset.
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for this class of drugs, as the use of Papp data obtained under isotonic
pH 7.4 conditions resulted in pronounced under-prediction of CLR for
half of basic drugs in the dataset, with predicted CLR b 35% of the
observed value (Supplementary Results Fig. S4.3).
Excluding drugs which were known/reported substrates of human
kidney transporters had negligible impact on the success of CLR predic-
tion (Table 3). In contrast, failing to account for the presence/absence of
microvilli expressed by Caco-2 cell monolayers and nephron tubular
cells resulted in reduced prediction success with only 27% of drugs
predicted within 3-fold of the observed CLR. Comparison of predictive
performances of different models stratiﬁed according to low, medium
and highly reabsorption drug status is shown in Table 4.
3.4. Empirical relationship between Freab′ and Papp and calibration
approach
The Hill model was ﬁtted to the observed Freab′ and Papp data for
the 45 drugs selected (Fig. 5). The best-ﬁt value and 95% conﬁdence
interval for Caco-2 Papp corresponding to Freab′ = 0.5 was estimated
to be 34.4 (28.9–39.9) × 10−6 cm/s. In addition, the Hill model was
ﬁtted to the Papp values and Freab′ predicted by the mechanistic tubu-
lar reabsorption model for 45 drugs. The resultant estimate of Papp
corresponding to Freab′ = 0.5 was 14.8 (14.3–15.2) × 10−6 cm/s.
In order to evaluate the application of Papp–Freab′ calibration
(Eq. (17)), 11 drugs were selected as reference ‘calibrator’ drugs
(Papp,ref) covering a representative range of Freab′ and Papp values
(Table 5). The remaining 34 drugs were treated as an internal
‘validation’ set. Following the ﬁtting of the Hill equation to observedFig. 5. Best-ﬁt curve and 90% conﬁdence interval of the Hill equation to the Papp and Freab′
data for 45 drugs (solid and dashed lines respectively). Symbols indicate neutral ( ), basic
( ), acidic ( ), zwitterion ( ) and amphoteric ( ) drugs. Drugs with negative values for
observed Freab′ are plotted as Freab′ = 0, as described in the text.Freab′ and Papp,ref data for these 11 reference drugs, the best-ﬁt estimates
for a2 and b2 were 2.74 and 33.1 × 10−6 cm/s. Thesewere used to calcu-
late values of Papp,calibrated for the validation dataset, and were subse-
quently applied for prediction of Freab′, Freab and CLR using the minimal
physiologically-based reabsorption model, as done initially. Use of this
calibrated approach led to considerable improvement in the predictive
performance with 31/34 drugs in the internal validation set predicted
within 3-fold of the observed CLR (gmfe=1.73, Fig. 6). Comparable suc-
cess was seen for the full dataset, with 41/45 drugs predicted within 3-
fold of the observed CLR, and reduced bias (gmfe = 1.65) compared to
the model before applying the Papp calibration. Particular improvement
in the prediction of CLR following the Papp–Freab′ calibration was
apparent for basic drugs, as 15/16 drugs were successfully predicted.
An increase in prediction accuracy was also observed for neutral drugs
(e.g., prednisone) and zwitterions (e.g., moxiﬂoxacin) with moderate
Papp values (20–40 × 10−6 cm/s). The calibration approach resulted in
marginal overall improvement in the prediction of CLR for drugs with
Freab N 0.75. However, substantial improvement was noted for 9/11
highly reabsorbed drugs (Freab N 0.9), including isoxicam, probenecid,
caffeine and antipyrine.
4. Discussion
4.1. Physiological considerations for predicting tubular reabsorption
The 5-compartment minimal physiologically-based model was
developed for the prediction of tubular reabsorption. Although static,
the model accounted for physiological differences between regions of
the nephron and captured complex underlying physiology of the kidney
in a mechanistic manner. In addition to the model development, a
comprehensive database of physiological parameters with relevance
to pharmacokinetics of drugs in human kidney was collated.
Quantitative humanphysiological datawere sparse in general and avail-
able from a few primary research articles, butwere supported by data in
preclinical species where possible (see Supplementary Methods,Table 5
Reference drugs used for calibration of Caco-2 Papp data.
Drug CLR
(mL/min)
Freab Papp,ref
(×10−6 cm/s)
Papp,ref,calibrateda
(×10−6 cm/s)
Ionisation
at pH 6.5
Antipyrine 1.22 0.99 124.9 229.49 Neutral
Caffeine 1.06 0.99 81.12 94.06 Neutral
Chlorpropamide 0.56 0.91 88.12 111.60 Acid
Linezolid 39.5 0.58 36.1 17.65 Neutral
Oxprenolol 9.35 0.44 29.95 12.00 Base
Oxytetracycline 90.8 0.02 0.85 0.01 Zwitterion
Ribavirin 110 0.08 1.55 0.03 Neutral
Sparﬂoxacin 21.7 0.73 49.83 34.35 Zwitterion
Theophylline 5.50 0.91 65.13 59.75 Neutral
Tocainide 67.5 0.18 19 4.68 Base
Voriconazole 1.57 0.97 96.51 134.68 Neutral
a Papp,ref,calibrated calculated using Eq. (15) after ﬁtting of the Hill equation to the Caco-2
Papp data and either observed or predicted (using minimal model of reabsorption) Freab.
Fig. 6. Prediction of CLR using the minimal model following calibration of Papp data using
reference drugs (n = 45 drugs). Symbols indicate neutral ( ), basic ( ), acidic ( ),
zwitterion ( ) and amphoteric ( ) drugs in the internal ‘validation’ dataset and drugs
in the reference dataset (●; n = 11). Solid and dashed lines represent line of unity and
3-fold error, respectively. The inset shows the data for lower CLR values for clarity.
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ﬁltration rate, considerable inter-individual variability, as well as bias
in some of the commonly used methods has been reported (Delanaye
et al., 2012; Soveri et al., 2014; Sterner et al., 2008). The lack of data
and information on variability in reported values for physiological
parameters will inevitably result in a level of uncertainty associated
with the relevant input model parameters. For example, calculation of
apparent Freab was dependent on the value of GFR; the sensitivity of
Freab to changes in GFR was evident for drugs exhibiting low tubular
reabsorption (Freab b 0.25). However, as the reported data on the
inter-individual variability in GFR were limited in the clinical studies
in the database, its potential impact on the estimation of apparent
Freab was not considered in the current analysis.
Predictive performance of the mechanistic tubular reabsorption
model was assessed against a representative set of 45 drugs, focusing
in particular on the impact of the tubular surface area in the model de-
velopment (Tables 1 and 4). The mechanistic tubular reabsorption
model was applied to predict both regional and overall Freab′ for the se-
lected dataset. The analysis has shown that reabsorption in the proximal
tubule compartment was themajor contributor to the overall predicted
Freab for most of the drugs. Consideration of tubular reabsorption solely
in this region within the model had marginal impact on the prediction
of CLR for drugs with low Freab (e.g., atenolol and melagatran). In con-
trast, this approach resulted in reduced CLR prediction accuracy com-
pared with the ultimate 5-compartment model for extensively
reabsorbed drugs such as antipyrine and isoxicam (Table 4). The reab-
sorption in other tubular regions was not considered in the previously
reported static model (Kunze et al., 2014). However, it is important to
note that in the study by Kunze et al. only one drug in the dataset exhib-
ited notable net reabsorption (desipramine, apparent Freab of 0.31) and
drugs showing extensive reabsorption (Freab′ ~ 1, CLR approaching 1–
2 mL/min, (Tucker, 1981)) were not included in the analysis.
The 5-compartment tubular reabsorptionmodel was also able to ac-
count for regional differences in the expression of microvilli and subse-
quent effect on the surface area to be used for scaling of permeability
data. A pronounced under-prediction of CLR was observed for most of
the drugs in the dataset if differences in microvilli related surface area
between Caco-2 monolayers and the loop of Henle, distal tubule and
collecting duct regions were ignored (Supplementary ResultsFig. S.4.4); the exceptions were drugs with low Papp (e.g., melagatran).
All of the above emphasises the necessity for appropriate interpretation
and implementation of complex physiological features of human kidney
in the model to allow mechanistic prediction of CLR.
4.2. Validity of Caco-2 cell monolayers as in vitro model for renal tubular
reabsorption
The ability to cross biological membranes is an important determi-
nant of rate of absorption and rate and route of elimination (Smith
et al., 2014; Varma et al., 2015). Existing in vitro proximal tubulemodels
express a range of functional drug transporters, confounding measure-
ment of passive permeability in the nephron (Brown et al., 2008;
Fouda et al., 1990; Kunze et al., 2014). Although primary cultured
collecting duct cells can be used for this purpose, thesemethods require
a consistent supply of high quality kidney tissue (Triﬁllis and Kahng,
1990). Caco-2 cell monolayer assay performed in the presence of a
transporter inhibitor cocktail is widely used to measure passive
permeability and was therefore considered in the current work.
Alternatively, permeability data obtained in MDCK cells (Avdeef and
Tam, 2010; Irvine et al., 1999) can be considered for prediction of
Freab. The application of the MDCK data in this model would require ad-
equate implementation of the microvilli/surface area considerations
highlighted, together with the use of transporter inhibitor cocktail in
the in vitro assay to minimise the impact of differences in endogenous
transporter expression on Papp data.
Beyond inter-system differences in permeability (e.g. Caco-2 vs.
MDCK vs. nephron tubule cells), inter-laboratory variability has been
widely reported for experimental data generated in either Caco-2 or
MDCK cells (Artursson et al., 2001; Bentz et al., 2013). Reference com-
pounds are often used to standardise in vitro assay data and minimise
the impact of this variability on the subsequent IVIVE (Artursson et al.,
2001; Hasegawa et al., 2003; Sohlenius-Sternbeck et al., 2012). The
Papp–Freab′ calibration approach proposed here can be used in that con-
text. While this method resulted in the improved prediction of CLR
(Fig. 6 and Table 4), the choice of drugs used as reference dataset was
fundamental. As such, the Papp–Freab′ calibration proposed here should
be applied with caution; further work is needed to reﬁne and validate
this approach using an external dataset of Caco-2 (or MDCK) Papp data.
The Caco-2 permeability data were measured under a pH-gradient
in order to mimic the slightly acidic nature of urine typically found
in vivo. The pH consideration was particularly important for basic
drugs because the use of permeability data under iso-pH conditions re-
sulted in systematic under-prediction of CLR for this class (Supplemen-
tary Results, Fig. S4.3). However, despite the use of the pH-gradient, an
apparent over-prediction of Freab was still evident for some basic drugs,
mostly those with moderate Papp (approx. 20–40 × 10−6 cm/s). Two
pH-related mechanisms could potentially contribute to this under-
prediction. Firstly, a reduced fraction of unionised drug in acidic
conditions may affect the permeation rate of the total (ionised and
unionised) drug. Secondly, the concentration gradient of the unionised
basic drug in vivo could be reduced in acidic conditions (due towater re-
absorption), or in extreme cases reversed which would not be repre-
sented by the typical in vitro permeability assay. Additionally, it is
important to consider that if left uncontrolled, urine pH can vary sub-
stantially in clinical studies (Özdemir et al., 2004), which can confound
subsequent pharmacokinetic analyses and estimation of CLR and Freab
used for model validation. Finally, potential contribution of tubular re-
absorption via active transport in vivo via as yet unknown transporter-
substrate interactions should not be disregarded.
4.3. Application of the mechanistic tubular reabsorptionmodel and existing
gaps
Use of the mechanistic tubular reabsorption model in conjunction
with in vitro permeability data in a pure ‘bottom-up’ manner resulted
69D. Scotcher et al. / European Journal of Pharmaceutical Sciences 94 (2016) 59–71in CLR prediction accuracy comparable with quantitative structure-
pharmacokinetic relationships and allometric approaches. In contrast
to other methods, the added advantage of this IVIVE approach is the
mechanistic insight into renal drug elimination because of the physio-
logical nature of the model. This model provides solid foundation to
inform future PBPK efforts towards understanding mechanisms behind
changes in CLR following pathophysiological changes in kidney, by
accounting for the effects of factors such as age and renal impairment
on the values of physiological parameters. For example, the lengths of
each region of the tubule used in themodel are representative of values
reported for the healthy adult population (see Table S1.4 in the
supplementary methods). Proximal tubule length has been reported
to change with age (Darmady et al., 1973; Fetterman et al., 1965).
Accounting for this, as well as any changes in other physiological
parameters, could be used to investigate potential differences in tubular
reabsorption in paediatric and geriatric populations.
Accuracy of CLR prediction using the tubular reabsorptionmodelwas
consistent across all ionisation groups, with a slightly higher bias seen
for acidic drugs (Table 3). CLR was over-predicted by more than 4-fold
for three drugs (antipyrine, caffeine and isoxicam), which all had
apparent Freab values ≥0.99. For these drugs, predicted CLR were very
sensitive to even minor relative changes in Freab. However, the
differences between predicted and observed CLR for drugs with very
high Freab represented ≤15% of the plasma clearance of these drugs in
healthy subjects, as they are also extensively metabolised by the liver
(Huffman et al., 1974; Shaw et al., 1985; Tang-Liu et al., 1982).
Therefore, potential errors in prediction of CLR for extensively
reabsorbed drugs were less likely to have a substantial impact on the
prediction of the overall in vivo clearance for such drugs.
The dataset used for model assessment here included several drugs
(e.g., caffeine, antipyrine) which are extensively reabsorbed and are
known to exhibit urine ﬂow and pH dependent CLR (Birkett and
Miners, 1991;Mawer and Lee, 1968; Taylor and Blaschke, 1984). It is be-
yond capability (and purpose) of the model to describe/predict urine
ﬂow dependent CLR quantitatively, as reported by some of the previous
modelling efforts (Hall and Rowland, 1984; Neuhoff et al., 2013;
Tang-Liu et al., 1983). However, modulation of the TFRCD and urine
ﬂow rate parameters in the model can be used to indicate whether a
drug is expected to exhibit urine ﬂow dependent CLR, as shown by the
sensitivity analysis presented in Supplementary Results, Fig. S4.5. It is
anticipated that incorporation of the mechanistic prediction of tubular
reabsorption into existing PBPK kidney models, e.g., (Neuhoff et al.,
2013), will allow for more accurate predictions of changes in tubular
reabsorption and CLR due to changes in urine ﬂow rates.
IVIVE of renal metabolic clearance has been investigated in several
studies (Gill et al., 2012, 2013; Knights et al., 2016). In contrast,
prediction of CLR,sec using ‘bottom-up’ approach is currently challenging
due to lack of a ‘gold standard’ in vitro system and physiologically
relevant scaling factors (Felmlee et al., 2013; Hsu et al., 2014; Kunze
et al., 2014; Posada et al., 2015; Watanabe et al., 2011). Static models
of CLR,sec (Watanabe et al., 2011) could be used alongside the current
reabsorption model for prediction of CLR; however, such an approach
is unlikely to be adequatewhenmetabolism is simultaneously involved.
Consideration of metabolism and secretion was outside of the scope of
the currentmodel, but these elements could potentially be incorporated
by expansion of the current model. While such expansion would not be
beneﬁcial for the majority of drugs investigated in the current study, it
might be of interest for probenecid which has high apparent Freab
(0.955) and may undergo renal glucuronidation (Vree et al., 1993).
Dynamic models, such as PBPK kidney models, which feature reabsorp-
tion, secretion and metabolism processes can be adapted/reﬁned to
incorporate mechanistic description of tubular reabsorption using the
principles of the current model. Although some PBPK kidney models
allow for metabolism-transport interplay to be investigated (Neuhoff
et al., 2013), obtaining suitable clinical data to validate such models
remains challenging (Tucker, 1981). Finally, considering a conservationof the tissue level organisation between mammalian species (e.g.,
regional differentiation of nephron), the mechanistic tubular reabsorp-
tionmodel could be adapted for prediction of Freab and CLR in preclinical
species, by accounting for speciﬁc differences in surface area and ﬂow
rate parameters.
4.4. Conclusion
A novel 5-compartment mechanistic tubular reabsorption model
was developed for prediction of Freab and CLR from Caco-2 Papp data. A
database of clinical CLR values for 157 drugs was collated, as well as a
comprehensive database of physiological parameters with relevance
to IVIVE of renal excretion clearance. Themechanisticmodel successful-
ly predicted CLR for 45 chemically diverse drugs for which ﬁltration or
reabsorption appeared to be the dominant mechanism. In addition,
empirical Papp–Freab′ calibration method was proposed to account for
inter-assay variability in permeability data. The physiological
assumptions of themodel represent an excellent basis for future studies,
e.g., simultaneous consideration of secretion and reabsorption for
mechanistic predictions of CLR and prediction of Freab in different
pathophysiological conditions (e.g., renal impairment). Overall, the
mechanistic model represents an important addition to the currently
existing IVIVE toolbox, and a step towards enabling physiologically-
based predictions of renal tubular reabsorption, and its contribution to
CLR.
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